These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22321215)

  • 1. Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
    Hirata Y; Hirata M; Kawaratani Y; Shibano M; Taniguchi M; Yasuda M; Ohmomo Y; Nagaoka Y; Baba K; Uesato S
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1926-30. PubMed ID: 22321215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
    Kiyokawa S; Hirata Y; Nagaoka Y; Shibano M; Taniguchi M; Yasuda M; Baba K; Uesato S
    Bioorg Med Chem; 2010 Jun; 18(11):3925-33. PubMed ID: 20452226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
    Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
    Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
    Rajak H; Kumar P; Parmar P; Thakur BS; Veerasamy R; Sharma PC; Sharma AK; Gupta AK; Dangi JS
    Eur J Med Chem; 2012 Jul; 53():390-7. PubMed ID: 22541394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
    Cheng C; Yun F; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
    Lu A; Luo H; Shi M; Wu G; Yuan Y; Liu J; Tang F
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4924-7. PubMed ID: 21741834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Synthesis and anti-tumor activities of N-(aminopyridine) benzamide derivaties].
    Feng J; Li JQ
    Yao Xue Xue Bao; 2009 Dec; 44(12):1376-82. PubMed ID: 21351472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
    Zhang Q; Lu B; Li J
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3162-3166. PubMed ID: 28532668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
    Jaboin J; Wild J; Hamidi H; Khanna C; Kim CJ; Robey R; Bates SE; Thiele CJ
    Cancer Res; 2002 Nov; 62(21):6108-15. PubMed ID: 12414635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.
    Rossi C; Fincham CI; D'Andrea P; Porcelloni M; Ettorre A; Mauro S; Bigioni M; Binaschi M; Maggi CA; Nardelli F; Parlani M; Fattori D
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6767-9. PubMed ID: 21978679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities.
    Zhang Z; Zhang Q; Zhang H; Jiao M; Guo Z; Peng X; Fu L; Li J
    Bioorg Chem; 2021 Dec; 117():105407. PubMed ID: 34653945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
    Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
    Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
    Lee HY; Tsai AC; Chen MC; Shen PJ; Cheng YC; Kuo CC; Pan SL; Liu YM; Liu JF; Yeh TK; Wang JC; Chang CY; Chang JY; Liou JP
    J Med Chem; 2014 May; 57(10):4009-22. PubMed ID: 24766560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.
    Liu YM; Lee HY; Chen CH; Lee CH; Wang LT; Pan SL; Lai MJ; Yeh TK; Liou JP
    Eur J Med Chem; 2015 Jan; 89():320-30. PubMed ID: 25462248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities.
    Maeda T; Nagaoka Y; Kuwajima H; Seno C; Maruyama S; Kurotaki M; Uesato S
    Bioorg Med Chem; 2004 Aug; 12(16):4351-60. PubMed ID: 15265487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.
    Feng J; Fang H; Wang X; Jia Y; Zhang L; Jiao J; Zhang J; Gu L; Xu W
    Cancer Biol Ther; 2011 Mar; 11(5):477-89. PubMed ID: 21263218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.